The investigators utilized a development cohort to identify a single or a multi-parameter algorithm with three components: fluid index, breath index, and personalization parameters. Using all three parameters yielded a sensitivity of 65%, a specificity of 90%, and a false positive rate of 0.7 events per patient-year. Though this technology seems quiet promising as a continuous noninvasive surveillance, the failure rate of the device was approximately 45%, reflecting the need for further enhancements. Additionally, the concept of a wearable external device Inhibitors,research,lifescience,medical on a constant basis will have compliance issues for widespread use. If feasible, such technology might have a role for a defined
period post discharge. Specialized implantable devices also have been studied with the sole objective of monitoring impedance and arrhythmias to decrease hospitalization. In the Chronicle Offers Management to Inhibitors,research,lifescience,medical Patients with Advanced Signs and Symptoms
of Heart failure (COMPASS-HF) study,14 a fully implantable device — similar to the pulse generator of a pacemaker — was implanted in patients with both reduced and preserved ejection fraction. This system had the ability to continuously monitor and transmit right ventricular hemodynamic parameters. Of all the hemodynamic data collected, the right ventricular pressure at the time of pulmonary valve opening had a strong correlation with actual pulmonary Inhibitors,research,lifescience,medical artery pressures. Inhibitors,research,lifescience,medical These data were reviewed at least once a week, and intervention occurred accordingly. There was no significant change in the primary endpoint of HF-related events (hospitalizations, emergency room and urgent care visits needing IV diuretics). A retrospective analysis of the COMPASS-HF data did show a 36% reduction of a first HF-related hospitalization. When estimating intracardiac Docetaxel supplier pressures as a surrogate marker of an acute decompensation of HF, it has been shown that the left atrial pressure is
an accurate correlate of increased symptoms of shortness of breath. Though the use of Inhibitors,research,lifescience,medical continuous hemodynamic monitoring in the inpatient setting has been a controversial topic, it generally is agreed that the estimation of left atrial pressures will lead to early detection next of fluid overload state. The recent CHAMPION trial15 utilized a wireless sensor deployed into the distal pulmonary artery that could continuously transmit wedge pressure. At 6 months, there was a significant 28% reduction of the rate of HF-related hospitalizations. The outcome was similar in patients with preserved or low ejection fraction. The safety profile was favorable with a 98.6% freedom from device-related or system-related complications. Though there was a significant positive impact found in this study,15 the device was not approved since the FDA concluded that the positive results of the trial were undermined by the fact that the sponsor intervened to a degree that exceeded the research protocol.